Nicotine e-cigarettes outperform patches and gum for quitting smoking

Researchers have found that nicotine e-cigarettes help more smokers quit than traditional nicotine replacement therapies like patches and gum. A review of 14 systematic studies from 2014 to 2023 shows consistent high-quality evidence favoring nicotine vapes. The findings highlight gaps in research on long-term risks and comparisons to other treatments.

A team led by Dr. Angela Difeng Wu from the University of Oxford's Nuffield Department of Primary Care Health Sciences analyzed 14 systematic reviews on smoking cessation methods. The highest-quality studies consistently demonstrated higher quit rates with nicotine e-cigarettes compared to nicotine patches, gum, lozenges, non-nicotine e-cigarettes, and behavioral support programs alone. Lower-quality research showed more mixed results, but the strongest evidence supports nicotine e-cigarettes as more effective. The work, published in the journal Addiction, was funded by Cancer Research UK. Dr. Wu stated, 'We hope this overview and Evidence and Gap Map can lay to rest some claims that evidence is mixed regarding the impacts of nicotine e-cigarettes on smoking abstinence. In fact, the evidence is clear and consistent across all of the meta-analyses we consulted: e-cigarettes are effective at helping people stop smoking.' Researchers created an Evidence and Gap Map to identify research needs. No high-quality reviews compare nicotine e-cigarettes to cytisine, bupropion, or nicotine pouches, and evidence against varenicline comes from just one small, high-bias study. Data on serious adverse events remains uncertain, and most studies focus on high-income countries. The authors call for more research on risks and diverse populations.

Связанные статьи

Drug commissioner Hendrik Streeck at press conference urging ban on sweet-flavored e-cigarettes to safeguard youth from addiction.
Изображение, созданное ИИ

Комиссар по наркотикам Штреек призывает запретить сладкие ароматизаторы в электронных сигаретах

Сообщено ИИ Изображение, созданное ИИ

Комиссар федерального правительства по наркотикам Хендрик Штреек выступает за запрет сладких вкусов в электронных сигаретах для защиты молодежи. Он критикует маркетинг как стратегию формирования зависимости и приветствует планируемый запрет 13 ингредиентов. Однако исследователь зависимостей Хейно Стёвер считает эти меры необоснованными.

Law 2354 of 2024 aims to regulate nicotine electronic systems and similar products, but its implementation faces significant delays. Two years after promulgation, key provisions like mandatory labeling and advertising bans remain unenforced. This allows uncontrolled circulation of vapes among teens, per Ministry of Justice data.

Сообщено ИИ

China's State Tobacco Monopoly Administration released a draft policy on Thursday to reduce excess capacity in the e-cigarette sector and tighten enforcement of production and export standards. This follows a State Council opinion earlier this month that imposed stricter oversight on e-cigarettes and nicotine pouches.

A new study from the University of Gothenburg shows that tirzepatide, the active ingredient in the diabetes and weight loss drug Mounjaro, reduces alcohol intake and relapse-like behaviors in rats and mice. This builds on prior research on semaglutide in Ozempic and Wegovy, which curbs alcohol consumption in humans. Researchers hope for similar effects in patients with alcohol dependence.

Сообщено ИИ

A new review of clinical trials suggests that psychedelics like psilocybin are effective for treating depression but offer no advantage over traditional antidepressants. Researchers accounted for the challenge of blinding in psychedelic studies, where participants can often tell if they received the drug. The findings indicate similar outcomes when compared to unblinded antidepressant trials.

British American Tobacco is shutting down its Heidelberg manufacturing plant in South Africa, leading to 230 job losses, as it shifts to importing cigarettes amid a booming illicit trade. At the same time, the company is continuing an aggressive share buyback program in London to reward shareholders. Workers and experts point to government inaction on illegal cigarettes as a key factor in the decline.

Сообщено ИИ

A comprehensive review of clinical trials suggests that cannabis products high in THC may provide modest, short-term relief for chronic pain, especially neuropathic types, but with notable side effects. In contrast, CBD-dominant products offer no clear advantages. Researchers call for more long-term studies to assess safety and efficacy.

 

 

 

Этот сайт использует куки

Мы используем куки для анализа, чтобы улучшить наш сайт. Прочитайте нашу политику конфиденциальности для дополнительной информации.
Отклонить